Immuneering

Teva purchases 51% equity share of Immuneering

Wednesday, August 5, 2015

Jerusalem-based Teva Pharmaceutical Industries has entered into an agreement to purchase a 51% equity share of Immuneering, a Cambridge, Mass.-based genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.

[Read More]